Phosphodiesterase-5 inhibitors (PDE-5 inhibitors) for erection problems
References
Citations
Webber R (2005). Erectile dysfunction. Clinical Evidence (13): 1120–1127.
Gresser U, Gleiter CH (2002). Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil. European Journal of Medical Research, 7(10): 435–446.
Porst H, et al. (2003). Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology, 62(1): 121–125.
Seftel AD, et al. (2004). Erectile dysfunction: Etiology, evaluation, and treatment options. Medical Clinics of North America, 88(2): 387–416.
Cheitlin MD, et al. (1999). Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC/AHA expert consensus document. Circulation, 99(1): 168–177.
Shakir SAW, et al. (2001). Cardiovascular events in users of sildenafil: Results from first phase of prescription monitoring in England. BMJ, 322(7287): 651–652.
Arruda-Olson AM, et al. (2002). Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA, 287(6): 719–725.
Webster LJ, et al. (2004). Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure. Archives of Internal Medicine, 164(5): 514–520.
| Author: | Douglas Dana Ralph Poore | Last Updated: August 24, 2006 |
| Medical Review: | Adam Husney, MD - Family Medicine Tom Bailey, MD - Family Medicine Christopher G. Wood, MD, FACS - Urology/Oncology | |
 | ||
| |
| Topic Contents | |
| Examples | |
| How It Works | |
| Why It Is Used | |
| How Well It Works | |
| Side Effects | |
| What To Think About | |
| References | |